Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 21, 2025 13:50 ET | Source: Abvance Therapeutics

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia
September 25, 2024 08:30 ET | Source: Entera Bio Ltd.; OPKO Health, Inc.

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO)...
February 03, 2022 14:35 ET | Source: Industry Research

Glucosamine Market and Glucagon Market Overview 2022: Leading Players Updates, Consumer-Demand Status, Consumption, Recent Developments, Business Strategies, Market Pulse, Screener , Indexes, Impact & Forecast till 2027 | Industry Research

Pune, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Global Glucosamine Market Analysis and Insights: The global Glucosamine market was valued at USD 231.9 million in 2020 and it is expected to reach USD 304.8...
May 26, 2021 01:30 ET | Source: Adocia SA

泵给药短效多激素组合专利申请将Adocia临床研究扩展到肥胖症领域

已申请三项专利系列涵盖新型激素组合：普兰林肽-艾塞那肽和胰高血糖素-艾塞那肽——两种组合在肥胖症治疗中均显示出令人鼓舞的效果通过泵输注短效激素可以增强患者授权，使患者可以优化治疗的获益/风险比这些配方也可以用于治疗其他代谢性疾病，例如NASH（非酒精性脂肪性肝炎），2型糖尿病或神经退行性疾病里昂, May 26, 2021 (GLOBE NEWSWIRE) -- Adocia...
May 26, 2021 01:30 ET | Source: Adocia SA

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

Three patent families have been filed to cover novel hormonal combinations: pramlintide-exenatide and glucagon-exenatide – both combinations demonstrated promising effects in obesity...
March 08, 2018 18:00 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. Completes $55 million In New Financing To Support Ready-To-Use Glucagon Development

CHICAGO, IL, March 08, 2018 (GLOBE NEWSWIRE) -- CHICAGO, IL; March 8, 2018 (GLOBE NEWSWIRE) – Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel...
February 15, 2018 17:00 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia

Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...
September 07, 2017 16:30 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of Directors

Chicago, IL and Austin, TX, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for...
June 16, 2017 07:51 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program

CHICAGO, IL and AUSTIN, TX, June 16, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) announced today that results from three clinical studies of the company’s investigational...
June 05, 2017 08:15 ET | Source: Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions

CHICAGO, IL and AUSTIN, TX; , June 05, 2017 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”) today announced that data from the company’s non-aqueous, room temperature stable, ready to use...

Next Page keyboard_arrow_right